Phase II Comparative Study of Myocet Plus Cyclophosphamide in First Line Treatment of HER2 Negative Metastatic Breast Patients

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT01885013

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-28T10:36:02.105128+00:00

Published At

2016-01-01T00:00:00+00:00

Record Updated At

2016-01-01

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Human Epidermal Growth Factor 2 Negative Carcinoma of Breast"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2016-01-01"

protocolSection.identificationModule.nctId

"NCT01885013"

protocolSection.identificationModule.officialTitle

"Phase II Comparative Study of Myocet Plus Cyclophosphamide in First Line Treatment of HER2 Negative Metastatic Breast Patients"

protocolSection.statusModule.overallStatus

"COMPLETED"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• Human Epidermal Growth Factor 2 Negative Carcinoma of Breast (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.